The Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines

Ilyas, Amber; Hashim, Zehra; Naeem, Nadia; Haneef, Kanwal; Zarina, Shamshad

doi:10.1155/2014/532953

Cited by 14 publications

(8 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many chemotherapeutic drugs have been used for the treatment of HCC and it has own implicated therapeutic effect. Alendronate is pyrophosphate analogues which, one of the potential anticancer drug [17].…”

Section: Introductionmentioning

confidence: 99%

Identification of Differential Protein Expression in Hepatocellular Carcinoma Induced Wistar Albino Rats by 2D Electrophoresis and MALDI-TOF–MS Analysis

et al. 2015

View full text Add to dashboard Cite

Hepato cellular carcinoma (HCC) is a type of malignant tumor. To investigate the proteins in cancer molecular mechanism and its role in HCC, we have used proteomic tools such as 2DE and MALDI-TOF-MS. Our investigation ravels that, plasma α-fetoprotein and carcinoembryonic antigen levels were elevated in DEN induced rats and gradually decreased after the treatment with 1,3BPMU. 2DE and MALDI-TOF-MS tool offers to identify the up and down regulation of proteins in HCC. Proteomic study reveals that, five differentially expressed proteins were identified in DEN induced rats and 1,3BPMU treated rats i.e. three up regulated protein such as T kininogen, NDPKB, PRMT1 (DEN induced rats), RGS19 and PAF (1,3BPMU treated rats) in 3BPMU treated rats, activation of transcription of a single gene from multiple promoters provides flexibility in the controlled gene expression. The regulations of hepatocyte stimulating factor were slow down the proliferation of hepatic cell and uncontrolled hepatic cell growth and also molecular signals strongly argue for a patho-physiological role in liver metastasis to control the cell aggression. This indicates that, anti cancer property of 1,3BPMU can be used as potent anti cancer agent. The present study also shows the proteomic approach helps to elucidate the tumor maker as well as regulatory marker proteins in HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of Differential Protein Expression in Hepatocellular Carcinoma Induced Wistar Albino Rats by 2D Electrophoresis and MALDI-TOF–MS Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Besides MVA pathway inhibitor, bisphosphonates (BPs)have inhibitory bone resorption property and studies also suggested there anticancer activity in various cancer including breast cancer [16,17]. BPs exert their effects through inhibition of bone resorption and bone-derived growth factors that ultimately results in inhibition of tumor cell invasion [18], proliferation [19] and increased apoptosis [20] [15,28].…”

Section: Discussionmentioning

confidence: 99%

“…supplemented with 10% fetal bovine serum (Sigma) and 100 μg/mL of penicillin and streptomycin (Life technologies Inc.) in a free gas exchange with atmospheric air at 37 0 C.Drug TreatmentCells were in exponential growth phase, subjected for drug treatment. The concentration of alendronate was calculated on the basis of previous studies[14,15]. Cells were treated with 5µM, 10 µM, 20 µM Alendronate (ALN).…”

mentioning

confidence: 99%

Assessment of Anticancer Effect of Alendronate in Breast Cancer: An In vitro Study

Ilyas

Zarina

Hashim

2019

JBBS

Self Cite

View full text Add to dashboard Cite

Breast cancer has high incidence in women from both developed and developing countries. Approximately 2 million women are diagnosed with breast cancer in 2018. In Asia, unfortunately Pakistan leads the highest number of breast cancer patients. Various treatment strategies are present but they are not well developed. There is a great need to develop effective methods for early detection and treatment of the disease. For cancer treatment chemotherapeutic interventions have always been a method of choice. One of the mechanisms involved in cancerous cell proliferation is Mevalonate (MVA) pathway. It is hypothesized that arresting MVA pathway leads to cell death hence cancer cell growth is suppressed. Various inhibitors of MVA pathway have been studied that can suppress cell proliferation. Nitrogen containing bisphosphonates are MVA pathway inhibitor and clinically used for treatment of bone diseases. Their anticancer efficacy is also reported. Current study focuses on alendronate, a nitrogen containing bisphosphonate to examine their anticancer effect on breast cancer cell line. Results of this study may help in addition of new anticancer drug for breast cancer.

show abstract

“…after treatment with ALD has also been observed [27]. ALD inhibited the proliferation of the Huh-7 hepatocellular carcinoma cell lines in a time and dose dependant manner at concentrations between 5-20 μM [28]. ALD has also been shown to have anti-proliferative effect on the epidermoid carcinoma cell line A431, as well as inhibiting cell invasion in a matrigel invasion assay [29].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy

Hodgins

Wang

Al‐Jamal

2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Nitrogen containing bisphosphonates (N-BPs) including zoledronate (ZOL) and alendronate (ALD) inhibit farnesyl diphosphate synthase, and have been shown to have a cytotoxic affect against cancer cells as a monotherapy and to also sensitise tumour cells to destruction by γδ T cells. γδ T cells are a subset of human T lymphocytes and have a diverse range of roles in the immune system including the recognition and destruction of cancer cells. This property of γδ T cells can be harnessed for use in cancer immunotherapy through in vivo expansion or the adoptive transfer of ex vivo activated γδ T cells. The use of N-BPs with γδ T cells has been shown to have a synergistic effect in in vitro, animal and clinical studies. N-BPs have limited in vivo activity due to rapid clearance from the circulation. By encapsulating N-BPs in liposomes (L) it is possible to increase the levels of N-BPs at non-osseous tumour sites. L-ZOL and L-ALD have been shown to have different toxicological profiles than free ZOL or ALD. Both L-ALD and L-ZOL led to increased spleen weight, leucocytosis, neutrophilia and lymphocytopenia in mice after intravenous injection. L-ALD was shown to be better tolerated than L-ZOL in murine studies. Biodistribution studies have been performed in order to better understand the interaction of N-BPs and γδ T cells in vivo. Additionally, in vivo therapy studies have shown that mice treated with both L-ALD and γδ T cells had a significant reduction in tumour growth compared to mice treated with L-ALD or γδ T cells alone. The use of ligand-targeted liposomes may further increase the efficacy of this combinatory immunotherapy. Liposomes targeting the αvβ6 integrin receptor using the peptide A20FMDV2 had a greater ability than untargeted liposomes in sensitising cancer cells to destruction by γδ T cells in αvβ6 positive cancer cell lines.

show abstract

The Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines

Cited by 14 publications

References 52 publications

Identification of Differential Protein Expression in Hepatocellular Carcinoma Induced Wistar Albino Rats by 2D Electrophoresis and MALDI-TOF–MS Analysis

Identification of Differential Protein Expression in Hepatocellular Carcinoma Induced Wistar Albino Rats by 2D Electrophoresis and MALDI-TOF–MS Analysis

Assessment of Anticancer Effect of Alendronate in Breast Cancer: An In vitro Study

Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy

Contact Info

Product

Resources

About